Skip to main content
. Author manuscript; available in PMC: 2013 Mar 6.
Published in final edited form as: Lancet Neurol. 2008 Aug;7(8):742–755. doi: 10.1016/S1474-4422(08)70165-0

Figure 4.

Figure 4

Current and emerging NMDAR-based strategies for treatment of neurological diseases. These strategies include NMDAR antagonism, decreasing glutamate release by inhibiting presynaptic voltage-gated Na+ and/or Ca2+ channels, enhancing glutamate uptake from the synaptic cleft by excitatory amino acid transporter (EAAT) on neurons and glia, and targeting intracellular signalling molecules associated with synaptic or extrasynaptic NMDARs. Currently used drugs or drugs being studied (in gray italics) which target these sites are indicated.